Jena D. French, PhD, instructor of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, discusses combination regimens exploring immunotherapy and lenvatinib (Lenvima) as treatment for patients with thyroid cancer.

Targeting PD-1 with monotherapy has been successful in several tumor types, French explains. However, it does not produce a complete response throughout an entire patient population. Additionally, lenvatinib has been shown to demonstrate good partial responses in patients; therefore, PD-1 antibodies and lenvatinib combined could show promising efficacy levels.

French says that combination therapies will become a bigger focus in the future treatment landscape of thyroid cancer.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Head & Neck Cancers

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer. 

Immuno-Oncology

Jena D. French, PhD, instructor of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, discusses combination regimens exploring immunotherapy and lenvatinib as treatment for patients with thyroid cancer.

Jena French on Combinations With Immunotherapy in Thyroid Cancer